Aptinyx's Mid-Stage NMDA Receptor Fails to Hit Endpoints in Neuropathic Pain Study - BioSpace

Submitted by Anonymous (not verified) on Wed, 01/16/2019 - 15:24

Aptinyx's Mid-Stage NMDA Receptor Fails to Hit Endpoints in Neuropathic Pain Study  BioSpaceShares of Illinois-based Aptinyx Inc. have plunged more than 67 percent in premarket trading after the company announced its mid-stage treatment for painful ...